Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019050521 - DOSING REGIMENS OF BI-SPECIFIC CD123 X CD3 DIABODIES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

Publication Number WO/2019/050521
Publication Date 14.03.2019
International Application No. PCT/US2017/050471
International Filing Date 07.09.2017
IPC
A01N 65/00 2006.01
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
65Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2809
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2809against the T-cell receptor (TcR)-CD3 complex
C07K 16/2866
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2866against receptors for cytokines, lymphokines, interferons
Applicants
  • MACROGENICS, INC. [US]/[US]
Inventors
  • WIGGINTON, Jon, Marc
  • ALDERSON, Ralph, Froman
  • LECHLEIDER, Robert, Joseph
Agents
  • AUERBACH, Jeffrey, I.
  • SCHROT, William, C.
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) DOSING REGIMENS OF BI-SPECIFIC CD123 X CD3 DIABODIES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
(FR) SCHÉMAS POSOLOGIQUES DE DIACORPS BISPÉCIFIQUES CD123 X CD3 DANS LE TRAITEMENT DE MALIGNITÉS HÉMATOLOGIQUES
Abstract
(EN)
The present invention is directed to a dosing regimen for administering a CD123 x CD3 bi-specific monovalent diabody to patients with a hematologic malignancy such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The invention particularly concerns the use of such a regimen for the sequence-optimized CD 123 x CD3 bi-specific monovalent diabody "DART-A," that is capable of simultaneous binding to CD 123 and CD3.
(FR)
La présente invention concerne un schéma posologique d’administration d’un diacorps monovalent bispécifique CD123 x CD3 à des patients présentant une malignité hématologique telle qu’une leucémie myéloïde aiguë (AML) ou un syndrome myélodysplasique (MDS). L’invention concerne particulièrement l’utilisation d’un tel schéma pour le diacorps monovalent bispécifique CD123 x CD3 à séquence optimisée "DART-A," qui est capable de liaison simultanée à CD123 et CD3.
Latest bibliographic data on file with the International Bureau